The medicine Vigoril is a medication that is applied across domains where additional symptomatic support is needed. This medication is commonly used across conditions presenting with acute episodes of systemic or localized discomfort, and its primary therapeutic domains involve easing symptoms related to systemic imbalance.

This medicine may be part of symptomatic management for conditions characterized by periods of heightened symptoms. Its main applications include erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). In both cases, the medication is considered relevant for easing symptoms that interfere with daily functioning.

For patients experiencing PAH, the medicine is relevant for easing the heightened physiological strain linked to organ-specific functional stress. The medication is used in settings marked by temporary physiological imbalance. For men with ED, the medication may assist with the inability to achieve or maintain an erection, and provides supportive relief when symptoms interfere with routine activities. This supportive assistance may help patients cope more steadily with symptom fluctuations in scenarios where short-term symptomatic assistance is needed.

---

Category of Benefit: Helps address symptoms related to physical discomfort

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use Vigoril — Official Regulatory Information

The following population eligibility rules are strictly based on government-approved labeling for the active ingredient, Sildenafil.

Eligibility scope	Official Regulatory Status
Populations for whom use is allowed	Adults (males and females) for approved conditions, and pediatric patients 1 to 17 years old for the pulmonary arterial hypertension (PAH) indication.
Populations for whom use is contraindicated	Patients using organic nitrates in any form, guanylate cyclase stimulators (e.g., riociguat), and individuals with known hypersensitivity to the formulation.
Populations for whom use is not recommended	Patients with certain hereditary degenerative retinal disorders (e.g., retinitis pigmentosa) and those with pulmonary veno-occlusive disease (PVOD).

Condition and Age-Related Restrictions

Age-related eligibility rules:

• Adults: Use is established for approved indications.
• Geriatric Patients (65 and older): Use requires caution, and a lower initial dose is typically considered due to age-related changes in drug clearance.
• Pediatric Patients: Safety and effectiveness have not been established in children younger than 1 year of age.

Condition-specific eligibility rules:

• Cardiovascular Status: The medicine is contraindicated in patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION), recent stroke or myocardial infarction, and resting hypotension (blood pressure less than 90/50 mmHg).
• Organ Impairment: Clearance is reduced in patients with severe renal impairment and hepatic impairment, necessitating special consideration by a healthcare professional.

Pregnancy and lactation eligibility status:

• Sildenafil is not indicated for the treatment of erectile dysfunction in females. For PAH, there are limited data; the risks of untreated PAH are often considered significant.

Connection to the overall eligibility profile

Regulatory documents define eligibility primarily by excluding populations where the drug's vasodilatory effects pose a life-threatening risk, such as patients taking nitrates. Eligibility is also strictly restricted based on organ function, with limits specified for severe hepatic and renal impairment due to the potential for increased drug exposure. Furthermore, age boundaries are defined, explicitly classifying use as "not established" in infants younger than one year of age.

Interactions with other medicines and products

Vigoril (sildenafil) can interact with certain medicinal products, which may significantly increase the risk of serious side effects, such as a severe drop in blood pressure. The drug's interaction profile is primarily defined by its effects on the nitric oxide/cGMP pathway and its metabolism via the cytochrome P450 enzyme system.

Contraindicated Combinations

• Nitrates and Nitric Oxide (NO) Donors: Vigoril is strictly contraindicated for use with any form of organic nitrates (e.g., nitroglycerin) or nitric oxide donors. This combination can cause a rapid, excessive, and potentially fatal decrease in blood pressure due to Vigoril's potentiation of the vasodilating effects of nitrates.

Pharmacokinetic Interactions (CYP3A4)

Vigoril is mainly cleared from the body by the CYP3A4 liver enzyme. The co-administration of CYP3A4 inhibitors increases the exposure of Vigoril in the plasma, raising the risk of dose-dependent adverse effects. For example, potent inhibitors like Ritonavir are contraindicated, while others such as Ketoconazole, Itraconazole, and Erythromycin require a mandatory dose reduction of Vigoril upon initiation. Conversely, co-administration with CYP3A4 inducers would be expected to decrease Vigoril exposure.

Pharmacodynamic Interactions

• Alpha-blockers and Antihypertensives: Co-administration with alpha-blockers (e.g., doxazosin) may lead to symptomatic hypotension. Vigoril should only be initiated at a low dose in patients who are hemodynamically stable on their alpha-blocker therapy.

How Vigoril Works

Vigoril's action is fundamentally based on selective enzyme inhibition within the vascular system. Its mechanism is an example of signal potentiation, where the drug amplifies a naturally occurring physiological process.

---

Selective Inhibition of the PDE5 Enzyme

Vigoril acts as a competitive inhibitor of the enzyme Phosphodiesterase type 5 (PDE5), which is involved in regulating smooth muscle tone in certain arteries. By blocking this enzyme, the drug prevents the breakdown of the signaling molecule cyclic Guanosine Monophosphate (cGMP), allowing it to accumulate. This mechanism directly affects molecular processes involved in vascular relaxation.

---

Potentiation of the NO-cGMP Pathway

The accumulation of cGMP activates a cascade that ultimately leads to the relaxation of vascular smooth muscle cells by reducing intracellular calcium levels. This entire action is conditional, meaning the mechanism only functions by prolonging the relaxing signal initiated by the release of Nitric Oxide (NO). The resulting physiological effect is localized vasodilation—a widening of the specific arteries—which facilitates local blood flow.

How to Use Vigoril

Administration of Vigoril (Sildenafil) is structured according to the specific condition being addressed, defining whether usage is intermittent or a fixed-schedule maintenance therapy. The medicine is available for oral administration as film-coated tablets (25 mg, 50 mg, 100 mg) and as a reconstituted oral suspension (10 mg/mL). An intravenous (IV) bolus injection (10 mg) is also an approved route, specifically used to temporarily continue treatment for pulmonary arterial hypertension (PAH) when oral intake is not possible.

---

Official Dosing and Frequency Patterns

Indication	Standard Regimen	Frequency and Timing
Erectile Dysfunction (ED)	Starting dose: 50 mg; Maximum dose: 100 mg	Taken as needed, approximately one hour before activity; maximum once per day.
Pulmonary Arterial Hypertension (PAH)	Standard dose: 20 mg; Maximum dose: 80 mg	Taken three times a day (TID), approximately 4 to 6 hours apart.

---

Procedural Administration Constraints

The tablets may be taken with or without food; however, consuming a high-fat meal may delay the onset of the medicine's activity for the ED indication. For the oral powder form, proper use requires reconstitution with water to achieve the correct concentration (10 mg/mL) and vigorous shaking prior to each dose measurement. For specific patient populations, including older adults (over 65 years) or those with severe kidney or liver impairment, a lower 25 mg starting dose is considered for the ED indication, reflecting official instructions for use in these groups. The medicine is intended for long-term use in PAH but is used on an intermittent basis for ED.

Research evidence / Overview of studies for Vigoril

Evidence for Use in Erectile Dysfunction (ED)

Research into Sildenafil (Vigoril) for Erectile Dysfunction (ED) primarily consists of controlled investigations, including randomized controlled trials (RCTs) and systematic reviews. These studies were designed to explore how functional measures change over time in adult male populations diagnosed with ED of various origins. Researchers have studied populations where ED was related to factors such as diabetes and post-surgical conditions, aiming to contextualize the findings for different patient profiles. The study outcomes examined included patient-reported measures of function, such as scores on the International Index of Erectile Function (IIEF), and data from patient diaries monitoring outcomes related to daily functioning.

Findings from these trials described patterns observed in the studies related to the short-term measurements, specifically the reported shifts in IIEF scores and other functional data over observation periods typically lasting between 4 and 12 weeks. While long-term extension studies were observed in some settings to track durability, follow-up durations were limited in the pivotal trials. Data for certain severe or rare subtypes of the condition may be insufficient.

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

For Pulmonary Arterial Hypertension (PAH), the evidence base includes randomized controlled trials (RCTs) and subsequent systematic reviews. These studies were evaluated in adults and in specific pediatric patients who present with symptomatic PAH. The research examined outcomes related to systemic or functional imbalance, such as changes in the patient's exercise capacity, typically measured using the 6-Minute Walk Distance (6MWD), and assessments of functional status.

Research highlights changes measured during the study period, with findings describing patterns related to the measured exercise capacity in observed groups, compared against control groups. Studies for pediatric populations explored short-term changes in hemodynamic parameters. Generalizability to all possible, less common subtypes of PAH is less characterized, and limited information exists for long-term survival data.

Research Landscape: Gaps and Unanswered Questions

Despite the existence of multiple RCTs, certain gaps and limitations exist in the overall research landscape. Evidence quality varies across studies, and long-term effects are not fully established, as follow-up durations were limited in some of the pivotal trials. The evidence base provides context but not individual predictions; findings describe group patterns, not personal outcomes. Research highlights what is known—and what is still uncertain—particularly concerning data for certain subgroups and comparative evidence against newer treatments.

Key Studies & References

1. Sildenafil - StatPearls - NCBI Bookshelf (General overview of indications, contraindications, and research scope)
2. Label: SILDENAFIL tablet (FDA Prescribing Information for Pulmonary Arterial Hypertension)

Common questions about Vigoril (FAQ)

Q: How quickly can I expect to feel the effects of Vigoril?

A: Official information indicates that for some conditions, the medicine is typically taken approximately one hour before activity. The one-hour recommendation is based on studies of how long the medicine typically takes to begin working, but individual patient response times can vary.

Q: What happens if I miss a dose of Vigoril?

A: The official instructions outline specific dosing schedules for each approved use but do not contain standardized directions for managing a forgotten dose. In the event of a missed dose, specific instructions on how to proceed are usually provided by the prescribing healthcare professional.

Q: Can Vigoril interact with common supplements like vitamins or herbal products?

A: The official product information primarily focuses on drug-drug interactions with specific classes, such as nitrates and strong CYP3A4 inhibitors. It does not provide detailed information about every possible interaction with over-the-counter supplements or herbal products. Information regarding the potential effects of supplements when taken with the medication is best obtained from a healthcare professional.

Q: Is Vigoril safe to take if I have diabetes?

A: Clinical studies for Vigoril included patient populations where the condition was related to factors such as diabetes. However, the official safety labeling does not contain specific cautions or contraindications related solely to diabetes. The decision for use in patients with diabetes is part of the clinical assessment performed by a healthcare professional.

Q: Can Vigoril be crushed or split?

A: Official directions specify that the product is supplied as a film-coated tablet for oral consumption. The tablets are manufactured to be swallowed whole unless specific, explicit instructions from the manufacturer or a prescriber state otherwise.

Q: Is Vigoril a treatment or just a way to manage symptoms?

A: According to official regulatory documents, Vigoril is indicated to treat specific conditions, such as Pulmonary Arterial Hypertension (PAH) and Erectile Dysfunction (ED). Its mechanism of action, by enhancing a natural physiological process, helps improve the functional measures associated with these conditions.

Q: Are the side effects of Vigoril common or rare?

A: Official documents classify adverse reactions by frequency. Headache and flushing are designated as Very Common, affecting more than 1 in 10 patients. More serious side effects, such as a sudden loss of vision or hearing, are reported as rare events.

Q: Does Vigoril cause drowsiness or affect driving?

A: Official product information reports adverse reactions like dizziness and certain visual disturbances. Due to the possibility of these effects, product information recommends individuals understand how they react to the medicine before operating vehicles or machinery.

Q: Can Vigoril cause issues with my stomach or digestion?

A: Yes, regulatory documents list upset stomach (dyspepsia) as a commonly reported side effect. The safety of the medicine is generally unknown in patients with active peptic ulceration or known bleeding disorders.

Q: Is it normal to feel a mild headache when first starting Vigoril?

A: Yes, headache is classified as a Very Common adverse reaction in the official safety documents, meaning it is one of the most frequently observed effects. This is thought to be related to the medicine's vasodilating action (widening of blood vessels).

Q: Are there any serious side effects of Vigoril I should be aware of?

A: Official warnings note the possibility of rare, serious adverse reactions. These include sudden vision loss caused by a condition called NAION, sudden decrease or loss of hearing, and priapism (an erection lasting longer than four hours).

Q: Does Vigoril affect sleep patterns?

A: Official adverse reaction reports indicate that insomnia (difficulty sleeping) is a known side effect that has been reported in patients taking Vigoril.

Q: Is Vigoril safe to take if I have high blood pressure?

A: Vigoril has vasodilatory properties, meaning it causes a mild and temporary decrease in blood pressure. Regulatory warnings indicate that use requires careful consideration by a healthcare professional, especially in patients who are taking other blood pressure medications or who have very low blood pressure.

Q: What is the published research or clinical trial evidence supporting Vigoril?

A: The efficacy of Vigoril is supported by published data from randomized, placebo-controlled clinical trials. These studies measured changes in functional outcomes, such as exercise capacity for PAH or specific patient-reported measures of function for ED.

Q: Can Vigoril cause changes in mood or anxiety levels?

A: Official safety information lists anxiety as an adverse reaction observed in clinical trials. Other effects on the nervous system, such as depression and abnormal dreams, have also been reported with an unknown frequency.

Q: Can Vigoril affect fertility?

A: Based on nonclinical toxicology studies, regulatory documents state that there was no evidence of impaired fertility observed in animal subjects.

Q: What are the official guidelines for prescribing Vigoril?

A: Official guidelines are comprehensive regulatory documents that provide essential information for healthcare professionals. These documents outline the specific indications, contraindications (who should not take it), warnings for special populations, and necessary dose adjustments based on organ function or drug interactions.

Q: Does Vigoril have any known long-term side effects?

A: The official safety profile includes adverse reactions reported both in short-term clinical trials and through long-term post-marketing surveillance. Clinical trials often have limited follow-up duration for definitively tracking effects over many years.

Q: How does the effectiveness of Vigoril compare between different age groups?

A: Clinical studies for the ED indication included a wide range of adults, including patients over 65 years old. Official documents conclude that studies have not identified age-specific problems that limit the medicine's overall usefulness in the elderly, though dose adjustments may be needed due to age-related changes in how the body processes the drug.

How to Store and Dispose of Vigoril

Storage Requirements

Vigoril tablets must be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container and tightly closed to protect it from excessive moisture and light. It is important not to refrigerate or freeze the product. For the oral suspension form, the constituted product has a limited stability and must be used within 60 days of mixing. All forms must be stored out of the reach of children.

Disposal Instructions

Expired or unused Vigoril should be returned through a drug take-back program if one is available. If no take-back program is accessible, the medicine can be disposed of in the household trash. This requires mixing the tablets with an unappealing substance, such as coffee grounds or cat litter, placing the mixture in a sealed container, and discarding it.